MedTrace Logo

ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer

NCT00010153 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-07-19

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases.

PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.

Conditions

Interventions

DRUG

fulvestrant

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • Breast International Group

    collaborator OTHER

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Cornelis J.H. van de Velde, MD, PhD, FRCS, FRCPS · Leiden University Medical Center

  • Anthony Howell, MD · The Christie NHS Foundation Trust

Study Design

Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Primary Completion
2001-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00010153 on ClinicalTrials.gov